SC
RVNC

Stephens Consulting’s Revance Therapeutics, Inc. RVNC Stock Holding History

Stephens Consulting’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500
Closed -$5.74K – 507
2023
Q3 		$5.74K Hold
500
– – ﹤0.01% 364
2023
Q2 		$12.7K Hold
500
– – 0.01% 285
2023
Q1 		$16.1K Hold
500
– – 0.01% 267
2022
Q4 		$9.23K Hold
500
– – 0.01% 310
2022
Q3 		$13.5K Hold
500
– – 0.01% 292
2022
Q2 		$6.91K Hold
500
– – 0.01% 375
2022
Q1 		$9.75K Hold
500
– – 0.01% 357
2021
Q4 		$8.16K Buy
+500
New +$8.34K 0.01% 423

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stephens Consulting's RVNC Position: Q4 2023 in Review

Stephens Consulting sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 500 shares — an estimated $5.74K sold.

Stephens Consulting first reported a position in RVNC in Q4 2021 and held it in 8 quarters. The position peaked at $16.1K in Q1 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

  • Stephens Consulting reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Stephens Consulting sold 500 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $5.74K.
  • Stephens Consulting first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 8 quarters.
  • Stephens Consulting's Revance Therapeutics, Inc. position peaked at $16.1K in Q1 2023.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Stephens Consulting's 13F filing for Q4 2023, filed 1 Feb 2024.